超声引导下单次注射治疗髋骨关节炎的疗效。
Efficacy of a single ultrasound-guided injection for the treatment of hip osteoarthritis.
机构信息
Northumbria Healthcare NHS Foundation Trust, Ashington, Northumberland, UK.
出版信息
Ann Rheum Dis. 2011 Jan;70(1):110-6. doi: 10.1136/ard.2009.127183. Epub 2010 Nov 10.
BACKGROUND
Intra-articular injection is effective for osteoarthritis, but the best single injection strategy is not known, nor are there established predictors of response. The objectives of this study were to assess and predict response to a single ultrasound-guided injection in moderate to severe hip osteoarthritis.
METHODS
77 hip osteoarthritis patients entered a prospective, randomised controlled trial, randomised to one of four groups: standard care (no injection); normal saline; non-animal stabilised hyaluronic acid (durolane) or methylprednisolone acetate (depomedrone).
MAIN OUTCOME MEASURES
Numerical rating scale (NRS 0-10) 'worst pain', Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain/function. Potential predictors of response (including radiographic severity, ultrasound synovitis and baseline symptom severity) were examined using univariate logistic regression analysis and Fisher's exact test.
RESULTS
NRS pain, WOMAC pain and function improved significantly for the steroid arm alone. Effect sizes at week 1 were striking: NRS pain 1.5, WOMAC pain 1.9 and WOMAC function 1.3. Outcome Measures in Rheumatoid Arthritis Clinical Trials-Osteoarthritis Research Society responder criteria identified 22 responders (intention-to-treat): steroid 14 (74%; number needed to treat, two); saline, four (21%); durolane, two (11%); and no injection, two (10%; χ(2) test between groups, p<0.001). Corticosteroid arm response was maintained over 8 weeks (summary measures analysis of variance, p<0.002 for NRS pain). Synovitis was a significant predictor of response at weeks 4 and 8 (p<0.05, Fisher's exact test; week 4 OR 16.7, 95% CI 1.4 to 204).
CONCLUSIONS
Ultrasound-guided corticosteroid injections are highly efficacious; furthermore synovitis on ultrasound is a biomarker of response to injection.
背景
关节内注射对骨关节炎有效,但最佳单次注射策略尚不清楚,也没有确定的反应预测因子。本研究的目的是评估和预测中度至重度髋骨关节炎单次超声引导注射的反应。
方法
77 例髋骨关节炎患者入组前瞻性随机对照试验,随机分为四组:标准治疗(无注射);生理盐水;非动物稳定透明质酸(杜罗兰)或甲基强的松龙醋酸酯(德普美龙)。
主要观察指标
数字评分量表(NRS 0-10)“最痛”,西安大略和麦克马斯特大学骨关节炎指数(WOMAC)疼痛/功能。使用单变量逻辑回归分析和 Fisher 精确检验检查反应的潜在预测因子(包括放射学严重程度、超声滑膜炎和基线症状严重程度)。
结果
单独使用类固醇组的 NRS 疼痛、WOMAC 疼痛和功能显著改善。第 1 周的效应量非常显著:NRS 疼痛 1.5,WOMAC 疼痛 1.9,WOMAC 功能 1.3。类风湿关节炎临床试验中的结局测量-骨关节炎研究协会反应标准确定了 22 名反应者(意向治疗):类固醇 14 名(74%;需要治疗的人数,2 名);生理盐水,4 名(21%);杜罗兰,2 名(11%);无注射,2 名(10%;组间 χ(2)检验,p<0.001)。在 8 周时,类固醇组的反应得到维持(NRS 疼痛的汇总测量方差分析,p<0.002)。滑膜炎在第 4 周和第 8 周是反应的显著预测因子(p<0.05,Fisher 精确检验;第 4 周 OR 16.7,95%CI 1.4 至 204)。
结论
超声引导下皮质类固醇注射非常有效;此外,超声滑膜炎是注射反应的生物标志物。